Immunosuppressive MDMs constitute a promising target for glioma treatment, whereas the enhancement of a microglia phagocytotic activity via Trem2 proved its efficacy in preclinical studies and is currently in a clinical phase 2 trial. The gene discussed is TREM2; the disease is central nervous system cancer.